Ribo presenta la solicitud para un ensayo clínico en Europa del estudio de fase I con el siRNA RBD3133

Phase 1RBD3133Positive

AI Analysis

Summary

Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals AB submitted a clinical trial application in Europe for Phase 1 study of siRNA RBD3133 targeting INHBE.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Clinical trial application submitted in Europe

Importance:5/10

Sentiment:

0.40

clinical trialsiRNAEuroperegulatory submission

Related Companies

$06938.HK

Read the original article

Published by PR Newswire Biotech on October 8, 2026 10:44 AM

Read Original